Jessica Fye
Stock Analyst at JP Morgan
(4.43)
# 367
Out of 5,036 analysts
213
Total ratings
60.74%
Success rate
14.77%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $474.00 | -0.21% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $32.86 | +131.28% | 4 | Oct 9, 2025 | |
| INCY Incyte | Maintains: Neutral | $73 → $89 | $87.30 | +1.95% | 9 | Oct 9, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $116 → $119 | $53.81 | +121.15% | 5 | Oct 9, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $260 → $264 | $200.59 | +31.61% | 16 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $517 → $530 | $426.27 | +24.33% | 10 | Oct 8, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $345 → $385 | $315.74 | +21.94% | 4 | Oct 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $49 → $80 | $71.64 | +11.67% | 7 | Oct 8, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $53 → $52 | $42.85 | +21.35% | 6 | Sep 24, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $116 → $121 | $106.89 | +13.20% | 13 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $68.98 | +11.63% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $31.45 | +11.29% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $165.31 | -18.34% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $63 | $66.88 | -5.80% | 14 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $422.53 | -21.90% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $33 → $26 | $27.49 | -5.42% | 13 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $6.99 | +86.11% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $33.57 | +48.94% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $14.13 | +98.16% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $137.50 | +52.00% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $16.96 | +41.51% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $15.31 | +95.95% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $34.68 | -62.51% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $59.38 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $9.45 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.79 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $19.94 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.51 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.47 | +1,396.60% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.44 | +386.11% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.05 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.59 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.01 | - | 1 | Feb 8, 2018 |
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $474.00
Upside: -0.21%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $32.86
Upside: +131.28%
Incyte
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $87.30
Upside: +1.95%
BioMarin Pharmaceutical
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $53.81
Upside: +121.15%
Ascendis Pharma
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $200.59
Upside: +31.61%
Vertex Pharmaceuticals
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $426.27
Upside: +24.33%
BeOne Medicines AG
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $315.74
Upside: +21.94%
Ionis Pharmaceuticals
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $71.64
Upside: +11.67%
Crinetics Pharmaceuticals
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $42.85
Upside: +21.35%
BioNTech SE
Sep 22, 2025
Maintains: Neutral
Price Target: $116 → $121
Current: $106.89
Upside: +13.20%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $68.98
Upside: +11.63%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $31.45
Upside: +11.29%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $165.31
Upside: -18.34%
Aug 7, 2025
Maintains: Neutral
Price Target: $60 → $63
Current: $66.88
Upside: -5.80%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $422.53
Upside: -21.90%
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $27.49
Upside: -5.42%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $6.99
Upside: +86.11%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $33.57
Upside: +48.94%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $14.13
Upside: +98.16%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $137.50
Upside: +52.00%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $16.96
Upside: +41.51%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $15.31
Upside: +95.95%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $34.68
Upside: -62.51%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $59.38
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $9.45
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.79
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $19.94
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.51
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.47
Upside: +1,396.60%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.44
Upside: +386.11%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $10.05
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.59
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $11.01
Upside: -